1 Subcutaneous administration of glucagon (1 and 0.5 mg/kg) 30 min before the injection of carrageenin or dextran into the rat's paw reduced oedema and the local exudation of Evans blue previously given intravenously. 2 The effect persisted after removal of the adrenal medulla but not after adrenalectomy. 3 When glucagon (1 mg/kg, s.c.) was given daily after a local reaction to Freund's adjuvant injected into the paw had developed, a decrease in the reaction was observed up to 12 days. Blood sugar levels remained within the normal range. 4 Glucagon may exert an anti-inflammatory effect through the release of adrenal corticosteroids and thus help modulate inflammatory reactions.
Introduction
An interplay of hormones seems to influence the development of inflammatory reactions (Garcia Leme & Schapoval, 1975) . Insulin may act as a pro-inflammatory agent (Garcia Leme, Hamamura, Migliorini & Leite, 1973b; Garcia Leme, B6hm, Migliorini & Souza, 1974) . Most of the actions of glucagon oppose those of insulin. The glucagonproducing alpha cells and the insulin-producing beta cells of pancreatic islets are regarded as a single functional unit performing opposing functions (Unger, 1970 ).
The present experiments were therefore undertaken to investigate whether glucagon affects inflammatory reactions.
Methods
Male Sprague Dawley (Holtzman) rats weighing between 200-250 g were used.
Production of oedema in rat paws Carrageenin (0.5 mg/ml) or dextran (1.0 mg/ml) was dissolved in distilled water and 0.1 ml injected into the subplantar area of one of the hind paws; the other was injected with 0.1 ml of 0.9% w/v NaCl solution (saline). The volumes of the paws up to the tibio-tarsal articulation were determined by plethysmography at various time intervals with a modification of the apparatus described by Winder, Wax & Been (1957) . Results 
Results
The subcutaneous administration of 0.5 or 1 mg/kg glucagon attenuated the development of oedema in paws injected with carrageenin or dextran 30 min later. Both doses of glucagon produced similar inhibition of the swelling ( Figure  la,b) , possibly because they were absorbed from subcutaneous tissue at similar rates. Measurement of paw volumes made 0.5, 1, 2, 4, 6 and 24 h after the injection of the irritants showed in glucagon-treated rats significantly less oedema than the controls (P < 0.01, Student's t test), with the exception of those obtained at 24 hours. Blood sugar levels, determined 30 min after glucagon (0.5 or 1.0 mg) were 94-142 and 97-147 mg/100 ml blood respectively, and 74-130 mg/i 00 ml blood in the control group.
The exudation of Evans blue was also reduced in animals given 1 mg/kg glucagon, subcutaneously, 30 min before the injection of carrageenin or dextran (Figure 1c,d (Figure 2b ). Daily administration of glucagon (1 mg/kg, s.c.) from the 3rd to 15th day after injection of Freund's adjuvant into the rat's paw, produced a decrease of the already developed oedema (P< 0.01, Student's t test). A similar reduction was produced by daily injections of indomethacin (2 mg/kg, i.p.) (Figure 3a) . In the three days following Freund's adjuvant injection rats lost some weight as compared to a control group. However, after this period, treated and untreated animals gained as much weight as the control group (Figure 3b ). Blood sugar levels determined in all groups at the beginning of the experiments and at days 6, 10 and 15 were within the normal range.
Discussion
Our results suggest that glucagon may have an anti-inflammatory action which is likely to depend on release of corticosteroids as it was ineffective in adrenalectomized rats.
Glucagon was effective when given before carrageenin or dextran or when given after the initial signs of adjuvant arthritis had developed. In the latter case daily doses of glucagon for 12 days were as effective as daily doses of indomethacin (2 mg/kg). However, indomethacin does not act through the release of corticosteroids (Garcia Leme & Schapoval, 1975) . As pointed out by Whitehouse (1973/74) , administration of a drug after the onset of inflammation bears more relationship to its potential use as an anti-inflammatory agent than prophylactic administration.
The daily administration of glucagon may impair the regulation of blood sugar levels. However, daily doses of glucagon (1 mg/kg, s.c.) did not produce a persistent deviation from the normal range. Serum concentrations of corticosterone were increased in rats after paw injections of carrageenin (Garcia Leme & Schapoval, 1975) .
Subcutaneous administration of corticosterone reduced the oedema resulting from a subsequent injection of carrageenin (Garcia Leme & Schapoval, 1975) and attenuated the vascular responses to histamine and 5-hydroxytryptamine given intradermally (Garcia Leme & Wilhelm, 1975 (Bloom, 1973) . Release of glucagon was also induced by stress (Bloom, Daniel, Johnston, Ogawa & Pratt, 1973) .
Catecholamine release from the adrenal glands does not seem to be required for the anti-inflammatory action of glucagon. However, in man, adrenaline stimulates glucagon secretion (Gerich, Karam & Forsham, 1973) .
Significant glucagon release during sympathetic nerve stimulation has been seen in the cat (Esterhuizen & Howell, 1970) , dog (Renold, 1972) and calf (Bloom, 1973; Bloom, Edwards & Vaughan, 1973) . Bloom et al. (1973) deduced from their results that any stimulus of sufficient intensity to constitute a 'stress' may cause a non-specific increase in sympathetic activity, which could raise plasma glucagon concentrations.
Similar mechanisms may occur during inflammatory reactions. Catecholamines from the adrenal glands or increased sympathetic activity may enhance glucagon secretion which in turn would increase blood levels of corticosteroids and thus suppress inflammation.
Stimulation of the hypothalamo-pituitaryadrenal axis with release of corticosteroids was observed during the early phases of acute inflammatory reactions (Garcia Leme & Schapoval, 1975) . Furthermore, insulin may act as a pro-inflammatory agent (Garcia Leme et al., 1973b; Garcia Leme et al., 1974) . It is interesting that adrenaline inhibits the release of insulin and stimulates the release of glucagon, both in vitro and in vivo (Malaisse, Malaisse-Lagae, Wright & Ashmore, 1967; Porte, 1967; Leclercq-Meyer, Brisson & Malaisse, 1971) . Glucagon may act as an endogenous anti-inflammatory hormone that could be of therapeutic value when administered in chronic inflammation.
